Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 971
Dapivirine Vaginal Ring Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of October 2025.
Prevention Option:
Cabotegravir Regulatory Approval
Regulatory approvals and those pending for cabotegravir as of October 2025.
Prevention Option:
Dapivirine Vaginal Ring Volume
DVR supply available to low- and middle-income countries as of October 2025.
Prevention Option:
Cabotegravir Volume
Allocation of non-commercial cabotegravir for PrEP supply in low- and middle-income countries, 2023-2026, as of October 2025.
Prevention Option:
Dapivirine Vaginal Ring Implementation
Ongoing and planned implementation studies for the dapivirine vaginal ring as of October 2025.
Prevention Option:
Cabotegravir Implementation
Implementation studies completed, ongoing, or planned for cabotegravir as of October 2025.
Prevention Option:
PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir.
Prevention Option:
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of October 2025.
Prevention Option:
Long-Acting PrEP: Priority Slides
Slides with the current status and proposed priorities for long-acting PrEP products, regulatory approvals, planning & budgeting, delivery, and much more.
Where We Are Now with LEN for PrEP
The chaos in foreign assistance programs (including discontinuation of major PrEP programs), cuts in staffing and new demands on donor commitments will make decisions on the procurement of LEN for PrEP more complex and uncertain.
Prevention Option:
showing 1-10 of 971